Aim: In this subanalysis of the EXPAND study, we evaluated the risks and benefits of rivaroxaban plus antiplatelet therapy (APT) for patients with non-valvular atrial fibrillation (NVAF) complicated by stable coronary artery disease (CAD), ischemic stroke, or peripheral artery disease (PAD).
Methods: From the EXPAND study population (n=7,141), patients with NVAF complicated by stable CAD (n=886), ischemic stroke (n=1,231), or PAD (n=160) were included. Patients complicated by any of them were set as ALL (n=2,030). Patients were all treated with rivaroxaban (10 or 15 mg/day) with (+) or without (−) APT. Efficacy outcomes were symptomatic stroke＋systemic embolism (SE), symptomatic stroke＋SE＋myocardial infarction＋cardiovascular death, and all-cause death. Safety outcomes included major and any bleeding. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated for differences between the APT(+) and APT(−) groups.
Results: There were no significant differences in the efficacy outcomes between the APT(+) and APT(−) groups in the ALL cohort or in the CAD and STROKE sub-cohorts. In the PAD subcohort, the HR [95% CI] for all-cause death in the APT(+) group increased (4.43 [1.05–18.71]; p=0.043). In the APT(+) group, the HR [95% CI] for any bleeding increased in the ALL cohort (1.28 [1.01–1.62]; p=0.044) and STROKE subcohort (1.42 [1.01–2.01]; p=0.047), and for major bleeding in the CAD subcohort (2.00 [1.01–3.93]; p=0.046).
Conclusions: Rivaroxaban with APT did not reduce ischemic outcomes in patients with stable CAD or ischemic stroke; however, it did increase the risk of bleeding in patients with stable CAD or ischemic stroke.
"}],"abstractLicenseFlag":"disallow"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1420282801196047232","@type":"Researcher","personIdentifier":[{"@type":"KAKEN_RESEARCHERS","@value":"30346978"},{"@type":"NRID","@value":"1000030346978"},{"@type":"NRID","@value":"9000021328450"}],"foaf:name":[{"@language":"en","@value":"Kaikita Koichi"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Division of Cardiovascular Medicine and Nephrology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki"},{"@language":"en","@value":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University"}]},{"@id":"https://cir.nii.ac.jp/crid/1410866040573256075","@type":"Researcher","foaf:name":[{"@language":"en","@value":"Uchiyama Shinichiro"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Clinical Research Center for Medicine, Center for Brain and Cerebral Vessels, Sanno Medical Center"}]},{"@id":"https://cir.nii.ac.jp/crid/1410866040573256073","@type":"Researcher","foaf:name":[{"@language":"en","@value":"Atarashi Hirotsugu"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Nippon Medical School"},{"@language":"en","@value":"Tama Nagayama Hospital"}]},{"@id":"https://cir.nii.ac.jp/crid/1410866040573256065","@type":"Researcher","foaf:name":[{"@language":"en","@value":"Inoue Hiroshi"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Saiseikai Toyama Hospital"}]},{"@id":"https://cir.nii.ac.jp/crid/1410866040573256074","@type":"Researcher","foaf:name":[{"@language":"en","@value":"Kitazono Takanari"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University"}]},{"@id":"https://cir.nii.ac.jp/crid/1410866040573256070","@type":"Researcher","foaf:name":[{"@language":"en","@value":"Yamashita Takeshi"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Cardiovascular Institute Hospital"}]},{"@id":"https://cir.nii.ac.jp/crid/1410866040573256066","@type":"Researcher","foaf:name":[{"@language":"en","@value":"Shimizu Wataru"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Cardiovascular Medicine, Graduate School of Medicine, Nippon Medical School"}]},{"@id":"https://cir.nii.ac.jp/crid/1410866040573256064","@type":"Researcher","foaf:name":[{"@language":"en","@value":"Ikeda Takanori"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Cardiovascular Medicine, Toho University Faculty of Medicine"}]},{"@id":"https://cir.nii.ac.jp/crid/1410866040573256068","@type":"Researcher","foaf:name":[{"@language":"en","@value":"Kamouchi Masahiro"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Health Care Administration and Management, Center for Cohort Study, Kyushu University Graduate School of Medical Sciences"}]},{"@id":"https://cir.nii.ac.jp/crid/1410866040573256072","@type":"Researcher","foaf:name":[{"@language":"en","@value":"Fukuda Koji"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Division of Heart Rhythm, International University of Health and Welfare Hospital, International University of Health and Welfare"}]},{"@id":"https://cir.nii.ac.jp/crid/1410866040573256067","@type":"Researcher","foaf:name":[{"@language":"en","@value":"Origasa Hideki"}],"jpcoar:affiliationName":[{"@language":"en","@value":"The Institute of Statistical Mathematics"}]},{"@id":"https://cir.nii.ac.jp/crid/1410866040573256071","@type":"Researcher","foaf:name":[{"@language":"en","@value":"Shimokawa Hiroaki"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Graduate School, International University of Health and Welfare"},{"@language":"en","@value":"Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"13403478"},{"@type":"EISSN","@value":"18803873"}],"prism:publicationName":[{"@language":"en","@value":"Journal of Atherosclerosis and Thrombosis"},{"@language":"ja","@value":"Ｊｏｕｒｎａｌ ｏｆ Ａｔｈｅｒｏｓｃｌｅｒｏｓｉｓ ａｎｄ Ｔｈｒｏｍｂｏｓｉｓ"},{"@language":"en","@value":"JAT"},{"@language":"en","@value":"J Atheroscler Thromb"},{"@language":"ja","@value":"Ｊ Ａｔｈｅｒｏｓｃｌｅｒ Ｔｈｒｏｍｂ"}],"dc:publisher":[{"@language":"en","@value":"Japan Atherosclerosis Society"},{"@language":"ja","@value":"一般社団法人 日本動脈硬化学会"}],"prism:publicationDate":"2025-02-01","prism:volume":"32","prism:number":"2","prism:startingPage":"176","prism:endingPage":"187"},"reviewed":"false","dcterms:accessRights":"http://purl.org/coar/access_right/c_abf2","url":[{"@id":"https://miyazaki-u.repo.nii.ac.jp/records/2001315"},{"@id":"https://www.jstage.jst.go.jp/article/jat/32/2/32_64681/_pdf"},{"@id":"https://search.jamas.or.jp/link/ui/2025325017"}],"availableAt":"2025-02-01","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Rivaroxaban","dc:title":"Rivaroxaban"},{"@id":"https://cir.nii.ac.jp/all?q=Antiplatelet%20therapy","dc:title":"Antiplatelet therapy"},{"@id":"https://cir.nii.ac.jp/all?q=Non-valvular%20atrial%20fibrillation","dc:title":"Non-valvular atrial fibrillation"},{"@id":"https://cir.nii.ac.jp/all?q=Stroke","dc:title":"Stroke"},{"@id":"https://cir.nii.ac.jp/all?q=Bleeding","dc:title":"Bleeding"}],"dcterms:subject":[{"subjectScheme":"Other","notation":[{"@language":"en","@value":"Antiplatelet therapy"}]},{"subjectScheme":"Other","notation":[{"@language":"en","@value":"Bleeding"}]},{"subjectScheme":"Other","notation":[{"@language":"en","@value":"Non-valvular atrial fibrillation"}]},{"subjectScheme":"Other","notation":[{"@language":"en","@value":"Rivaroxaban"}]},{"subjectScheme":"Other","notation":[{"@language":"en","@value":"Stroke"}]}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360020313830235904","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292620574299392","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1360294647154215808","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTH"}]},{"@id":"https://cir.nii.ac.jp/crid/1360583260252034048","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC)"}]},{"@id":"https://cir.nii.ac.jp/crid/1360583260254118144","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"European Stroke Organisation (ESO) guideline on pharmacological interventions for long-term secondary prevention after ischaemic stroke or transient ischaemic attack"}]},{"@id":"https://cir.nii.ac.jp/crid/1360583263015301120","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Effects of Rivaroxaban on Platelet Activation and Platelet–Coagulation Pathway Interaction"}]},{"@id":"https://cir.nii.ac.jp/crid/1360583263765296000","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Antithrombotic Therapy for Atrial Fibrillation and Coronary Artery Disease in Patients With Prior Atherothrombotic Disease: A Post Hoc Analysis of the AFIRE Trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855569051037312","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855570793154816","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Atrial Fibrillation Is Associated with Severe Acute Ischemic Stroke"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855570943563264","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons"}]},{"@id":"https://cir.nii.ac.jp/crid/1360857595396184960","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association"}]},{"@id":"https://cir.nii.ac.jp/crid/1360857760692597248","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Adverse outcomes in patients with atrial fibrillation and peripheral arterial disease: a report from the EURObservational research programme pilot survey on atrial fibrillation"}]},{"@id":"https://cir.nii.ac.jp/crid/1360864735212998144","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Antiplatelet therapy in atherosclerotic cardiovascular disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418520983079296","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Aspirin for the Prevention of Cardiovascular Events in Patients With Peripheral Artery Disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1361694368570172160","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981469078136832","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"The EXPAND study: Efficacy and safety of rivaroxaban in Japanese patients with non-valvular atrial fibrillation"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981470984094336","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262943614687360","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670320026459008","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Atrial fibrillation as an independent risk factor for stroke: the Framingham Study."}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204244154880","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Study Design and Baseline Characteristics of the EXPAND Study: Evaluation of Effectiveness and Safety of Xa Inhibitor, Rivaroxaban for the Prevention of Stroke and Systemic Embolism in a Nationwide Cohort of Japanese Patients Diagnosed as Non-Valvular Atrial Fibrillation"}]},{"@id":"https://cir.nii.ac.jp/crid/1390011030550455168","@type":"Article","resourceType":"letter","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"en","@value":"JCS/JHRS Guideline: Rivaroxaban Not Recommended for Patients With Nonvalvular Atrial Fibrillation and High Bleeding Risk ― Reply ―"},{"@value":"JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias"},{"@value":"JCS/JHRS Guideline: Rivaroxaban Not Recommended for Patients With Nonvalvular Atrial Fibrillation and High Bleeding Risk"},{"@value":"